NodThera's NLRP3 Inhibitor NT-0796 Meets Primary Endpoint of Inflammation Reversal in Phase Ib/IIa Trial in Obese Subjects with Cardiovascular Risk [Yahoo! Finance]
Blue Owl Capital Inc. Class A (OWL)
Company Research
Source: Yahoo! Finance
Brain-penetrant NLRP3 inflammasome inhibitor demonstrates highly significant and rapid reduction of key inflammatory marker CRP compared to placebo Reductions in multiple markers of cardiometabolic risk confirm profound anti-inflammatory effect of NT-0796 Most pronounced weight loss seen among high-risk subgroups Planning is underway for Phase II studies in obesity, Parkinson's disease and other cardiometabolic indications BOSTON, MA, June 12, 2024 - NodThera, a leading clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, today announces positive data from its Phase Ib/IIa cardiovascular risk study in inflamed obese subjects, evaluating the effects of its oral, brain-penetrant NLRP3 inflammasome inhibitor NT-0796, on inflammatory, cardiovascular and metabolic risk parameters. Obese subjects with elevated baseline C-reactive protein (CRP), measured using an hsCRP assay, were recruited. Elevated CRP is a key m
Show less
Read more
Impact Snapshot
Event Time:
OWL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OWL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OWL alerts
High impacting Blue Owl Capital Inc. Class A news events
Weekly update
A roundup of the hottest topics
OWL
News
- BNY introduces Alts Bridge Platform [Yahoo! Finance]Yahoo! Finance
- Blue Owl Capital launches digital platform for private market access [Wealth Professional (Canada)]Wealth Professional
- Blue Owl Capital Inc. (NYSE: OWL) is now covered by analysts at Wells Fargo & Company. They set an "equal weight" rating and a $18.50 price target on the stock.MarketBeat
- Blue Owl Capital Launches New Digital Learning, Implementation and Engagement Platform for Financial Advisors and Their ClientsPR Newswire
- Blue Owl Joins Debt Rush With Bond to Pay Down Credit Facilities [Financial Post (Toronto, Ontario, Canada)]Financial Post
OWL
Earnings
- 8/1/24 - In-Line
OWL
Sec Filings
- 9/26/24 - Form EFFECT
- 9/25/24 - Form 424B3
- 9/13/24 - Form 4
- OWL's page on the SEC website